Mepro Pharmaceuticals Private Limited - Company Profile

It is a pharma private limited company based in Surendra Nagar, Gujarat, India, established in 1982.
1982 Surendra Nagar, Gujarat, India Active
Last Updated:
Access Report
About Mepro Pharmaceuticals Private Limited

Mepro Pharmaceuticals Private Limited, a active private limited company, was established on 31 August 1982 in Surendra Nagar, Gujarat, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24231GJ1982PTC005451. Registered under ROC Roc Ahmedabad. it is unlisted. It has an authorized capital of ₹5.40 Cr and a paid-up capital of ₹5.35 Cr.

It upholds a compliant status. Employing 543 professional, Its leadership includes Prakash Navinchandra Shah (Director), Bharatkumar Chabildas Shah (Director), Suresh Chhabildas Shah (Director). Past directors included Prakash Navinchandra Shah, Bharatkumar Chabildas Shah, Suresh Chhabildas Shah. It holds ₹169.20 Cr open charges and ₹12.50 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at 1003 - Gidc Wadhwan, Surendra Nagar, Gujarat, 363035.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24231GJ1982PTC005451

  • Registration Number

    005451

  • Incorporation Date

    31 August 1982

  • Authorized Capital

    ₹5.40 Cr

  • Paid-Up Capital

    ₹5.35 Cr

  • ROC Code

    Roc Ahmedabad

  • Listing Status

    Unlisted

  • Company Status

    Active

Key Metrics
  • Authorised Capital ₹ 5.40 Cr
  • Paid Up Capital ₹ 5.35 Cr
  • Company Age 43 Year, 5 Months
  • Last Filing with ROC 31 Mar 2025
  • Open Charges ₹ 169.20 Cr
  • Satisfied Charges ₹ 12.50 Cr
  • Revenue Growth **** 20.64%
  • Profit Growth **** 142.48%
  • Ebitda **** 35.41%
  • Net Worth 26.91%
  • Total Assets **** 4.50%
Company report

Mepro Pharmaceuticals Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Mepro Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Mepro Pharmaceuticals Private Limited?
Current Directors
Name Designation Appointment Date Status
Prakash Navinchandra Shah Director 17 Jul 2004 Current
Bharatkumar Chabildas Shah Director 31 Aug 1982 Current
Suresh Chhabildas Shah Director 31 Aug 1982 Current
Vijay Chhabildas Shah Whole-Time Director 31 Aug 1982 Current
Rajesh Sumanlal Shah Director 30 Sep 1987 Current
Past Directors
Name Designation Cessation Status
Pramod Abcsdd Whole-Time Director 30 Sep 2019 Past
Pramod Abcsdd Whole-Time Director 30 Sep 2019 Past
Pramod Abcsdd Director 13 Oct 2012 Past
Pramod Abcsdd Director 23 Dec 2015 Past
Pramod Abcsdd Director 13 Oct 2012 Past
Pramod Abcsdd Company Secretary 31 Mar 2020 Past

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Mepro Pharmaceuticals.

Mepro Pharmaceuticals Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 20.64% increase. The company also saw a substantial improvement in profitability, with a 142.48% increase in profit. The company's net worth Soared by an impressive increase of 26.91%.

Mepro Pharmaceuticals revenue growth over time
Mepro Pharmaceuticals profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
 20.64%
*******
*******
*******
*******
Revenue from Operations
*******
 20.98%
*******
*******
*******
*******
Total Assets
*******
 4.50%
*******
*******
*******
*******
Profit or Loss
*******
 142.48%
*******
*******
*******
*******
Net Worth
*******
 26.91%
*******
*******
*******
*******
EBITDA
*******
 35.41%
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Mepro Pharmaceuticals?

In 2024, Mepro Pharmaceuticals had a promoter holding of 23.02% and a public holding of 76.98%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

Charges (Loans)
Open Charges

₹1,692,000,000.00

Satisfied Charges

₹124,990,000.00

Charges Breakdown by Lending Institutions
  • Others : 110.70 Cr
  • Yes Bank Limited : 58.50 Cr
Latest Charge Details
Date Lender Amount Status
05 Dec 2022 Others ₹5.00 Cr Open
17 Oct 2019 Yes Bank Limited ₹10.00 Cr Open
17 Oct 2019 Others ₹38.50 Cr Open
21 May 2019 Yes Bank Limited ₹10.00 Cr Open
21 May 2019 Yes Bank Limited ₹38.50 Cr Open

Explore comprehensive loan charge details -

How Many Employees Work at Mepro Pharmaceuticals?

Mepro Pharmaceuticals has a workforce of 543 employees as of Mar 29, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Mepro Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mepro Pharmaceuticals's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Mepro Pharmaceuticals
Recent Activity within the Organization
  • Annual General Meeting

    Progress on Mepro Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.

  • Balance Sheet

    The activity Mepro Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad. was completed.

  • Charges

    A charge with Others amounted to Rs. 5.00 Cr with Charge ID 100668963 was registered on 05 Dec 2022. was recorded as a recent event.

  • Charges

    The activity A charge with Yes Bank Limited of Rs. 10.00 Cr registered on 17 Oct 2019 with Charge ID 100300344 was modified on 21 Jul 2022. was completed.

  • Charges

    The activity A charge with Yes Bank Limited of Rs. 10.00 Cr registered on 21 May 2019 with Charge ID 100268524 was modified on 23 Mar 2022. was completed.

  • Charges

    The activity A charge with Yes Bank Limited of Rs. 38.50 Cr registered on 21 May 2019 with Charge ID 100268529 was modified on 23 Mar 2022. was completed.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Mepro Pharmaceuticals Private Limited?

The CIN of Mepro Pharmaceuticals Private Limited is U24231GJ1982PTC005451.

Where is Mepro Pharmaceuticals Private Limited headquartered?

Mepro Pharmaceuticals Private Limited is headquartered at 1003 - Gidc Wadhwan, Surendra Nagar, Gujarat, 363035.

When was Mepro Pharmaceuticals Private Limited incorporated?

Mepro Pharmaceuticals Private Limited was incorporated on 31 August 1982.

Who are the current directors of Mepro Pharmaceuticals Private Limited?

The current directors of Mepro Pharmaceuticals Private Limited are

What is the primary industry of Mepro Pharmaceuticals Private Limited?

The primary industry of Mepro Pharmaceuticals Private Limited is Manufacturing.

Is Mepro Pharmaceuticals Private Limited a listed company?

Mepro Pharmaceuticals Private Limited is unlisted.

What is the capital structure of Mepro Pharmaceuticals Private Limited?

The authorized capital of Mepro Pharmaceuticals Private Limited is ₹5.40 Cr, and the paid-up capital is ₹5.35 Cr.

What is the compliance status of Mepro Pharmaceuticals Private Limited?

The compliance status of Mepro Pharmaceuticals Private Limited is Compliant.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available